<scp>COVID</scp>‐19 in patients with myasthenia gravis

Anand, Pria; Slama, Michaël C.C.; Kaku, Michelle; Ong, Charlene; Cervantes‐Arslanian, Anna M.; Zhou, Lan; David, William S.; Guidon, Amanda C.

doi:10.1002/mus.26918

Cited by 118 publications

(187 citation statements)

References 22 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…1), suggesting that most MS treatments that largely exhibit limited persistent effects on the innate immune and CD8 T cell responses would have limited influence on COVID‐19. SARS‐CoV‐2 is eliminated by the majority of people with MS and other autoimmunities on immunotherapies, without significant consequences [34–56] (Table 1). Anti‐viral antibodies, notably those targeting the receptor binding domain of the viral spike protein, clearly neutralize the virus [57,58] and can contribute to the elimination of the primary SARS‐CoV‐2 infection in humans [58,59].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

Baker

Roberts

Pryce

et al. 2020

Clinical and Experimental Immunology

172

201

View full text Add to dashboard Cite

Based on the known and emerging biology of autoimmune diseases and COVID‐19, it was hypothesised that whilst B‐cell depletion should not necessarily expose people to severe SARS‐CoV‐2‐related issues, it may inhibit or blunt the protective immunity following infection and vaccination. This is supported clinically, as the majority of SARS‐CoV‐2 infected, CD20‐depleted people with autoimmunity, have recovered. However, in CD‐20 treated people until naïve B‐cells repopulate, based on B‐cell repopulation‐kinetics and vaccination responses, from published rituximab, and unpublished ocrelizumab (NCT00676715, NCT02545868) trial data shown here suggests that it may be possible to undertake dose‐interruption to maintain inflammatory disease control, whilst allowing effective vaccination against SARS‐CoV‐29, if and when an effective vaccine is available.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

Baker

Roberts

Pryce

et al. 2020

Clinical and Experimental Immunology

172

201

View full text Add to dashboard Cite

show abstract

“…In accordance with Neurologists we decided not to proceed with TPE in order to avoid depletion of putative protective antibodies and patients received intravenous Immunoglobulins (IVIg). In the literature 5 more cases of COVID-19 in MG patients have been described until now, none treated with TPE [10]. At the beginning of the pandemic, 4 CIDP patients were on maintenance TPE treatment, with different schedules.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Colpo

Astolfi²,

Tison

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

The recent Coronavirus Disease 2019 (COVID-19) outbreak has led to profound and rapid changes in the Italian and Veneto Region Healthcare System. This context also includes the quick reorganization which the Apheresis Unit (AU) of the Padova University Hospital, i.e. the Regional Reference Center for Therapeutic Apheresis (TA), had to face. Material and Methods: The study retrospectively evaluated the TA activity (procedures performed, patients treated and consultations) during the COVID-19 pandemic, from March to April 2020, comparing the activity in the same time period in 2018 and 2019. Results: In the period analyzed, a significant reduction in both the total number of procedures performed and of patients treated, respectively by 17 % and 16 % for the procedures and by 19 % and 20 % for patients treated compared to the same period of 2018 and 2019, respectively, was observed. A concomitant reduction in requests for TA consultation for new patients (both outpatients and inpatients) was observed, equal to 32 % and 21 % compared to 2018 and 2019, respectively. Conclusion: Many reasons determined the observed reduction in the TA activity during the recent COVID-19 outbreak. The AU itself was quickly reorganized in terms of location and supplies to allow for the appropriate COVID-19 patients care. Many non urgent cases, after multidisciplinary discussion between Clinicians and Apheresis Specialists, were deferred, maintaining close phone and e-mail contact with patients.

show abstract

“…Furthermore, myositis and myasthenia gravis are both autoimmune diseases that might coexist. 110 Pathophysiology. COVID-19-induced musculoskeletal manifestations can develop through direct and indirect mechanisms.…”

Section: Musculoskeletal System Manifestationsmentioning

confidence: 99%

Extrapulmonary Clinical Manifestations in COVID-19 Patients

Sarkesh

Sorkhabi

Baghi

et al. 2020

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

COVID-19 manifestations in symptomatic patients can be in the form of pneumonia, acute respiratory syndrome, and multiple organ dysfunction as well. Renal complications, gastrointestinal dysfunctions, endocrine system disorders, myocardial dysfunction and arrhythmia, neurological dysfunctions, dermatological symptoms, hematological manifestations, and thromboinflammation are among the reported extrapulmonary complications. Moreover, the presence of coagulopathy, excessive and dysregulated immune responses, and autoimmunity by COVID-19 patients is considerable. The pathogenesis of infection entails the entry of the virus via receptors on cells, principally angiotensin-converting enzyme 2 receptors. Direct virus damage coupled with indirect effects of viral infection including thromboinflammation, dysfunction of the immune system, and dysregulation of the renin-angiotensin system leads to multiple organ failure. This review outlines the extrapulmonary organ-specific complications and their pathophysiology and epidemiology.

show abstract

COVID‐19 in patients with myasthenia gravis

Cited by 118 publications

References 22 publications

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Extrapulmonary Clinical Manifestations in COVID-19 Patients

Contact Info

Product

Resources

About